Medical Foods for Inborn Errors of Metabolism Market is expected to reach US$ 5,768.79 Mn in 2027

Packets Segment to Grow at Faster CAGR during 2019–2027

According to our new research study on “Medical Foods for Inborn Errors of Metabolism Market Forecast to 2027- Covid-19 Impact and Global Analysis by Product, Age group, Disease, Forms, Packaging, and Distribution Channel” the market is expected to reach US$ 5,768.79 million in 2027 from US$ 2,507.80 million in 2019; it is estimated to grow at a CAGR of 11.2% from 2020 to 2027. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The growth of the global medical foods for inborn errors of metabolism market is attributed to the increasing incidence of inborn errors of metabolism and increasing preference towards dietary food supplements. However, limitations associated to medical foods for inborn errors of metabolism is the major factor hindering the market growth.

Based on packaging, the global medical foods for inborn errors of metabolism market is segmented into can, jar, packet, bottle, and others. The can segment held the largest share of the market in 2019. However, the packets segment is expected to grow at the highest CAGR during the forecast period. The ease of use provided by packet packaging offer lucrative opportunities for the growth of packet segment.

The global medical foods for inborn errors of metabolism market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Nestlé Health Science, Abbott, Reckitt Benckiser Group Plc, Ajinomoto Cambrooke, Inc., Solace Nutrition, Primus Pharmaceuticals, Inc., BioMarin Pharmaceutical, Danone SA, Galen Limited and PKU-MDmil are among the leading companies operating in the medical foods for inborn errors of metabolism market.

Medical Foods for Inborn Errors of Metabolism Market, by Region, 2019 (%)

---

Medical Foods for Inborn Errors of Metabolism Market to Grow at a CAGR of 11.2% to reach US$ 5,768.79 Mn Million from 2020 to 2027

Download Free Sample

---

Medical Foods for Inborn Errors of Metabolism Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Amino Acid, Glytactin with GMP, Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Low Protein Food, and Others); Age group (Infants, Weaning, Adolescent, and Adults); Disease (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Urea Cycle Disorders, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I, Renal Disease, Tyrosinemia Types I and II, and Others); Forms (Powder, Liquids, Gels, and Others); Packaging (Can, Jar, Packets, Bottle, and Others); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores, and Others); and Geography

The report segments medical foods for inborn errors of metabolism market as follows:

By Product

• Amino Acid
• Glytactin with GMP
• Amino Acid-Modified Infant Formula With Iron
• Low-Calcium/Vitamin D-free Infant Formula With Iron
• Low Protein Food
• Others

By Age Group

• Infants
• Weaning
• Adolescents
• Adults   

By Disease

• Phenylketonuria(PKU)
• Maple Syrup Urine Disease(MSUD)
• Homocystinuria
• Urea Cycle Disorders
• Methylmalonic Acidemia
• Organic Acidurias
• Propionic Acidemia
• Isovaleric aciDemia
• Disorders of Leucine Metabolism
• Glutaric Acidemia Type I
• Renal Disease
• Tyrosinemia Types I and II
• Others

By Forms

• Powder
• Liquid
• Gels
• Others

By Packaging

• Can
• Jar
• Packets
• Bottle
• Others 

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Drugstores
• Others

  By Geography

• North America
  • • US
    • Canada
    • Mexico
• Europe
  • • France
    • Germany
    • UK
    • Spain
    • Italy
    • Rest of Europe
• Asia Pacific (APAC)
  • • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of APAC
• Middle East & Africa (MEA)
  • • Saudi Arabia
    • UAE
    • South Africa
    • Rest of MEA
• South and Central America (SCAM)
  • • Brazil
    • Argentina
    • Rest of SCAM